Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
587 questions in 116 reviews · Eyes and Vision
current versionsNo studies 587 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Face‐down positioning vs other positioning Frequency of intervention‐related non‐ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments Face‐down positioning or posturing after pars plana vitrectomy for macula‐involving rhegmatogenous retinal… (2024) · Cochrane | no estimate extracted | NR | No studies |
Lutein with or without zeaxanthin vs placebo Resource use and costs · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane | no estimate extracted | NR | No studies |
Vitamin E vs placebo Progression to neovascular AMD · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane | no estimate extracted | NR | No studies |
Vitamin E vs placebo Progression to geographic atrophy · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane | no estimate extracted | NR | No studies |
Vitamin E vs placebo Quality of life · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane | no estimate extracted | NR | No studies |
Vitamin E vs placebo Resource use and costs · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane | no estimate extracted | NR | No studies |
Zinc vs placebo Quality of life · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane | no estimate extracted | NR | No studies |
Zinc vs placebo Resource use and costs · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane | no estimate extracted | NR | No studies |
Antioxidant multivitamin and mineral supplement vs placebo or no treatment Resource use and costs · people with AMD Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration (2023) · Cochrane | no estimate extracted | NR | No studies |
Antibiotics vs placebo Cost‐effectiveness of treatment · Participants with acute bacterial conjunctivitis Antibiotics versus placebo for acute bacterial conjunctivitis (2023) · Cochrane | no estimate extracted | NR | No studies |
Tissue plasminogen activator (t‐PA) vs standard treatment Quality of life measures at 1 month · people with acute non‐arteritic CRAO Interventions for acute non‐arteritic central retinal artery occlusion (2023) · Cochrane | no estimate extracted | NR | No studies |
Surgery vs botulinum neurotoxin injections Presence and quality of binocularity at 6 months · children with infantile esotropia Interventions for infantile esotropia (2023) · Cochrane | no estimate extracted | NR | No studies |
Topical aminocaproic acid vs placebo Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Topical aminocaproic acid vs placebo Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Topical aminocaproic acid vs placebo Adverse effects: systemic hypotension · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Systemic tranexamic acid vs control Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Systemic tranexamic acid vs control Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Systemic tranexamic acid vs control Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Systemic aminocaproic acid vs placebo Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Systemic tranexamic acid vs control Adverse effects: nausea · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Topical aminocaproic acid vs placebo Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema Medical interventions for traumatic hyphema (2023) · Cochrane | no estimate extracted | NR | No studies |
Botulinum toxin vs surgery Serious adverse events at 6 or 12 months · adults and children with strabismus Botulinum toxin for the treatment of strabismus (2023) · Cochrane | no estimate extracted | NR | No studies |
Botulinum toxin vs surgery Quality of life, as measured by validated instruments · adults and children with strabismus Botulinum toxin for the treatment of strabismus (2023) · Cochrane | no estimate extracted | NR | No studies |
Anti‐VEGF vs no anti‐VEGF Proportion of participants with relief of pain and resolution of redness, 1 year · people with neovascular glaucoma Anti‐vascular endothelial growth factor for neovascular glaucoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Anti‐vascular endothelial growth factor (anti‐VEGF) with or without pan‐retinal photocoagulation (PRP) vs PRP alone Loss of 3 or more lines of ETDRS visual acuity ‐ not reported · people with proliferative diabetic retinopathy Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD Complement inhibitors for age‐related macular degeneration (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham Change in quality of life at 1 year (NEI VFQ‐25 composite score) · adults with GA due to AMD Complement inhibitors for age‐related macular degeneration (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD Complement inhibitors for age‐related macular degeneration (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham Change in quality of life at 1 year (NEI VFQ‐25 composite score) · adults with GA due to AMD Complement inhibitors for age‐related macular degeneration (2023) · Cochrane | no estimate extracted | NR | No studies |
Device‐modified trabeculectomy vs standard trabeculectomy Postoperative mean visual field change at 1 year · people with glaucoma Device‐modified trabeculectomy for glaucoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Device‐modified trabeculectomy vs standard trabeculectomy Quality of life at 1 year · people with glaucoma Device‐modified trabeculectomy for glaucoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Telerehabilitation vs self‐training Clinical measures, such as reading speed or reading acuity at 6 months · people with any eye disease including optic nerve disease, age‐related macular degeneration, retinopathy of… Telerehabilitation for people with low vision (2023) · Cochrane | no estimate extracted | NR | No studies |
Telerehabilitation vs self‐training Compliance at 6 months · people with any eye disease including optic nerve disease, age‐related macular degeneration, retinopathy of… Telerehabilitation for people with low vision (2023) · Cochrane | no estimate extracted | NR | No studies |
Iridotomy vs no iridotomy Proportion of progressive visual field loss at 1 year · people with primary angle‐closure suspect Iridotomy to slow progression of visual field loss in angle‐closure glaucoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Iridotomy vs no iridotomy Medications: mean number of medications used to control IOP at 1 year · people with primary angle‐closure suspect Iridotomy to slow progression of visual field loss in angle‐closure glaucoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Iridotomy vs no iridotomy Quality of life measures · people with primary angle‐closure suspect Iridotomy to slow progression of visual field loss in angle‐closure glaucoma (2023) · Cochrane | no estimate extracted | NR | No studies |
Trifocal intraocular lenses vs bifocal intraocular lenses after cataract extraction among participants with presbyopia Mean contrast sensitivity (1 year) · people (> 30 years) with cataract and presbyopia Trifocal intraocular lenses versus bifocal intraocular lenses after cataract extraction among participants… (2023) · Cochrane | no estimate extracted | NR | No studies |
Trifocal intraocular lenses vs bifocal intraocular lenses after cataract extraction among participants with presbyopia Mean quality of life or visual function (measured using Visual Function Index‐14 tool) (1 year) · people (> 30 years) with cataract and presbyopia Trifocal intraocular lenses versus bifocal intraocular lenses after cataract extraction among participants… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 1: blue‐light filtering lenses vs non‐blue‐light filtering lenses Proportion of eyes or individuals that developed macular structural changes · adults Blue‐light filtering spectacle lenses for visual performance, sleep, and macular health in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings 1: blue‐light filtering lenses vs non‐blue‐light filtering lenses Colour discrimination, measured using the FM‐100 hue test · adults Blue‐light filtering spectacle lenses for visual performance, sleep, and macular health in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Incidence of a reduction in visual acuity of 10 ETDR letters or more · people with type 2 diabetes Fenofibrate for diabetic retinopathy (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Incidence of PDR · people with type 2 diabetes Fenofibrate for diabetic retinopathy (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mean vision‐related quality of life · people with type 2 diabetes Fenofibrate for diabetic retinopathy (2023) · Cochrane | no estimate extracted | NR | No studies |
Silicone hydrogel vs hydrogel soft contact lenses Mean change in patient‐reported comfort score from baseline using CLDEQ‐8 · adults with refractive errors Silicone hydrogel versus hydrogel soft contact lenses for differences in patient‐reported eye comfort and… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mean change in BCVA from baseline · people with large macular hole Pars plana vitrectomy with internal limiting membrane flap versus pars plana vitrectomy with conventional… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Speed of visual acuity improvement · people with large macular hole Pars plana vitrectomy with internal limiting membrane flap versus pars plana vitrectomy with conventional… (2023) · Cochrane | no estimate extracted | NR | No studies |
Topical ophthalmic anesthetic plus NSAID vs placebo Changes in mean participant‐reported ocular pain from baseline to 48 hours · corneal abrasion (post‐surgical) Topical ophthalmic anesthetics for corneal abrasions (2023) · Cochrane | no estimate extracted | NR | No studies |
Topical ophthalmic anesthetic plus NSAID vs placebo Changes in mean participant‐reported ocular pain from baseline to 72 hours · corneal abrasion (post‐surgical) Topical ophthalmic anesthetics for corneal abrasions (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Pseudophakia vs aphakia Amblyopia ‐ not reported · children younger than two years of age with bilateral congenital cataracts Surgical interventions for bilateral congenital cataract in children aged two years and under (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Pseudophakia vs aphakia Retinal detachment ‐ not reported · children younger than two years of age with bilateral congenital cataracts Surgical interventions for bilateral congenital cataract in children aged two years and under (2022) · Cochrane | no estimate extracted | NR | No studies |